StockData

biote vs Lifevantage

BTMD and LFVN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BTMD and LFVN compare

Lifevantage is the larger company, worth 1.7 times as much as biote ($59.9M against $35.6M).

On earnings, biote is cheaper: it trades at 9.9× trailing earnings, against 11.9× for Lifevantage.

biote grew revenue faster over the last twelve months (−7.8% versus −20.1% for Lifevantage).

biote keeps more of each dollar of sales as profit, with a net margin of 3.2% compared with 2.8% at Lifevantage.

Lifevantage pays a dividend yielding 4.0%; biote does not pay one.

Lifevantage scores higher on the StockData Score (20 against 8 for biote), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBTMDLFVN
Size and price
Market cap$35.6M$59.9M
Share price$0.990$4.78
Change, 1 year−60.7%−27.8%
Change, 5 years−89.8%−29.2%
Beta (5Y)1.960.59
Employees223223
StockData Score
Total score820 (better)
Valuation score46 (better)
Growth score01 (better)
Performance score24 (better)
Health score25 (better)
Dividend score04 (better)
Valuation
P/E9.9× (better)11.9×
P/S0.2× (better)0.3×
P/B–1.8×
EV/EBITDA8.3×5.1× (better)
P/FCF1.8× (better)9.0×
PEG–0.46
FCF yield55.9% (better)11.1%
Fair value$3.20$8.48
Margin of safety69.0% (better)43.6%
Growth
Revenue growth (TTM)−7.8% (better)−20.1%
Revenue growth, 5Y average–−3.7%
Net income growth (TTM)−81.3%−48.3% (better)
EPS growth (TTM)−88.9%−46.7% (better)
EPS growth, 5Y average–−15.0%
Profitability
Gross margin68.6%77.6% (better)
Operating margin8.0% (better)3.3%
Net margin3.2% (better)2.8%
FCF margin10.8% (better)3.7%
Return on equity–14.9%
Return on invested capital45.7% (better)30.8%
Financial health
Debt / equity–0.00
Net debt / EBITDA5.93–
Current ratio1.431.89 (better)
Altman Z-score1.872.54 (better)
Piotroski F-score66
Dividends and buybacks
Dividend yield–4.0%
Payout ratio19.9%46.2%
Years of dividend growth–1
Buyback yield–3.4%
Shareholder yield0.00%7.4% (better)
Ownership
Held by institutions36.6%47.2%
Held by insiders23.3%27.8%
Insider net buying, 12 months$202K (better)$6.0K
Short interest, % of float3.1%10.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.